` AVDL (Avadel Pharmaceuticals PLC) vs S&P 500 Comparison - Alpha Spread

AVDL
vs
S&P 500

Over the past 12 months, AVDL has underperformed S&P 500, delivering a return of -60% compared to the S&P 500's 0% growth.

Stocks Performance
AVDL vs S&P 500

Loading

Performance Gap
AVDL vs S&P 500

Loading
AVDL
S&P 500
Difference

Performance By Year
AVDL vs S&P 500

Loading
AVDL
S&P 500
Add Stock

Competitors Performance
Avadel Pharmaceuticals PLC vs Peers

S&P 500
AVDL
LLY
JNJ
NOVO B
ROG
Add Stock

Avadel Pharmaceuticals PLC
Glance View

Economic Moat
None
Market Cap
644.7m USD
Industry
Pharmaceuticals

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 66 full-time employees. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.

AVDL Intrinsic Value
16.56 USD
Undervaluation 60%
Intrinsic Value
Price
Back to Top